Abstract
113P - Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have